About Us


Molecular Targeting Technologies, Inc. (MTTI)

Our Mission: Translate novel radiopharmaceuticals for treatment and diagnosis of underserved diseases.

Our Targets:
• 177Lu-EBTATE for neuroendocrine tumor (NET), shows enhanced, low dose activity via extended in vivo residence time vs competitors*.

• 131I-SapC-DOPS nanovesicle for glioblastoma multiforme (GBM), readily crosses the blood brain barrier delivering a dual killing effect to brain tumors*.

• TDURA (TumorVue®), a single platform with multiple applications based on the cell death targeting molecule 99mTc-duramycin*.
*See pipeline page